

CV

Prof. Dr. med. David Capper
26.03.1979, Stuttgart, Germany

Institut für Neuropathologie
Charité - Universitätsmedizin Berlin
Charitéplatz 1 | 10117 Berlin
E-Mail: David.Capper@charite.de



Education/ Training

Institution	Year(s)	Degree
Otto Hahn Gymnasium, Nagold	1998	Baccalaureate
Medical School Tübingen, Germany	2000 - 2006	Medical degree "Approbation"
DFG Graduate College 686-1; University Tübingen, Germany	2003 - 2004 (12 months)	Scholarship for doctoral thesis
Doctoral thesis (Neuropathology) Tübingen	2004 - 2008	Summa cum laude

Positions and Employment

Institution and Location	Year(s)	Position
Institute of Brain Research, Tübingen, Germany	2007 - 2007 (6 months)	Residency neuropathology
Department of Neuropathology, University Zurich, Switzerland	2007 - 2008 (12 months)	Residency neuropathology
Department of Neuropathology, University Heidelberg, Heidelberg	Since 2008	Residency neuropathology
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ)	2010 - 2017	Non-compensation employee
Bord certification Neuropathology	2013 - 2017	Consultant Neuropathology University Hospital Heidelberg
Neuropathology Charite Berlin	Since April 2017	Professor for Molecular Neuropathology
German Cancer Consortium Berlin (DKTK), German Cancer Research Center (DKFZ)	Since April 2017	Faculty, Group leader molecular Neuropathology

Research focus

Neuropathology, genetics and biology of adult and paediatric brain tumors. Biomarker development. Development of mutations specific antibodies. Clinical trial support (national and international). Implementation of DNA methylation signatures for tumor classification.

Honors

2008	Summa cum laude for doctoral thesis (Eberhard-Karls-University Tübingen)
2012	Werner-Rosenthal-prize of the Deutsche Gesellschaft für Neuropathologie und Neuroanatomie (DGNN Young Investigator Award; 1.000€)
2012	Württembergischer Krebspreis der Dres. Bayerstiftung (Young Investigator Award, 10.000€)
2015	Cavanagh Prize of the British Neuropathological Society (Young Investigator Award, 2.000€)
2018	Curt Meyer Memorial award of the Berliner Krebsgesellschaft (10.000€)
2018	Berlin Institute of Health (BIH) Quest open data award (1.000€)
2018	Innovation prize of the Deutschen Hochschulmedizin e.V. (10.000€)

Other Experience and Professional Memberships

- cIMPACT: the consortium to inform molecular and practical approaches to CNS tumor taxonomy
- Member of the “Consensus and Editorial Meeting Working Group” for the Update of the 4th edition of the WHO Classification of Tumours of the Central Nervous System
- Member of the German Society for Neuropathology and Neuroanatomy (DGNN)
- Member of the Society for Neuro-Oncology

Citations, h-Index, i10-index (08.2018)

Name:	age	Articles	First / last authorship	Co-author	Total sum of citations	H Index	i10 Index
David Capper	39	163	17 first 10 last	136	6654	42	104

Top 5 publications

1. **Capper D#**, Jones, D T W.#, Sill, M#, Hovestadt, V#, [...] , von Deimling A*, Pfister, S M* DNA methylation-based classification of central nervous system tumours, Nature 2018. #Co-first authors *Co-last authors
2. Worst BC#, van Tilburg CM#, Balasubramanian GP#, Fiesel P#, [...] , **Capper D***, Pfister SM*, Jones DT*, Witt O*. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer. 2016 Sep;65:91-101. #Co-first authors * Co-last authors

3. Schindler G, **Capper D#**, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma, *Acta Neuropathol* 2011, 121:397-405. #Co-first authors
4. **Capper D**, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors, *Brain Pathol* 2010, 20:245-254.
5. **Capper D**, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A: Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody, *Acta Neuropathol.* 2011 Jul;122(1):11-9.

Scientific impact:

Dr. Cappers work has focussed on translational neuropathology from very early on. Focus of his work was on a refined tumour classification and on the development of practice changing diagnostic assays. The first attempts of this were by generating mutation specific antibodies against neuropathologically relevant mutations (IDH1 R132H and BRAF V600E). Both of these tests have become standard tests in worldwide pathological and neuropathological laboratories. In the last years Dr. Capper focussed on implementation of high throughput molecular assays in clinical routine either in a clinical translation trial setting (INFORM) or for daylily practice. This effort has led to the recent generation of a DNA methylation based brain tumour classifier that is currently stepwise entering diagnostic practice.

Dr. Capper was appointed as the youngest member of the "Consensus and Editorial Meeting Working Group" of the 2016 WHO classification of brain tumors and is the youngest member of cIMPACT (the consortium to inform molecular and practical approaches to CNS tumor taxonomy).